electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
April 21, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published...
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
April 20, 2022 08:30 ET
|
Odyssey Group Intl Inc.
Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on...
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
April 19, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for...
electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
April 12, 2022 08:00 ET
|
electroCore, Inc.
Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021March 31, 2022, cash balance of approximately $29.9M ROCKAWAY, N.J., April 12, 2022 ...
electroCore Announces Exclusive License Agreement with Teijin for Japan Territory
April 05, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an...
Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
March 31, 2022 08:30 ET
|
Odyssey Group Intl Inc.
Irvine, CA, March 31, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products,...
electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York
March 23, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief...
electroCore to Present at 2022 Maxim Virtual Growth Conference
March 22, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief...
electroCore Announces Fourth Quarter and Full Year 2021 Financial Results
March 10, 2022 16:01 ET
|
electroCore, Inc.
Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents of $34.7 million Company to host conference call...
electroCore Announces Changes to its Board of Directors
March 09, 2022 11:30 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein...